Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levodopa + standard care refers to the use of levodopa, a dopamine precursor, in combination with the usual non-experimental therapies for Parkinson's disease (PD). Levodopa is converted to dopamine in the brain and is considered the most effective pharmacologic treatment for alleviating motor symptoms such as bradykinesia and rigidity in PD. Standard care typically includes supportive measures like physical therapy, occupational therapy, speech therapy, and may include other medications as clinically indicated. Levodopa is often administered with a peripheral decarboxylase inhibitor (such as carbidopa) to increase its bioavailability in the brain and reduce side effects. The mechanism of action involves replenishing depleted dopamine levels in the striatum by providing a substrate that crosses the blood-brain barrier and is then converted into active dopamine[6][8][10]. This combination remains first-line therapy for symptomatic management of Parkinson's disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levodopa + standard care.